Triangle0.5 mL Candin®/injection (NCT05952934)
0.5 mL Candin®/injection trial for Squamous Cell Carcinoma of Head and Neck (NCT05952934). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults aged 18–100 with head-and-neck squamous-cell cancer, no evidence of disease, and curative treatment completed within 120 days.
The idea: test whether Candin, a Candida-antigen preparation that stimulates immune responses, reduces recurrence. Cancer use remains experimental. Patients are randomized three-to-one to Candin or saline placebo: seven injections, initially every three weeks, then every three months. Researchers compare recurrence over two years and collect immune and microbiome samples.
This phase 2 study plans 100 patients. Injections are planned for 80. Omar Atiq, University of Arkansas, leads six recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.